Latest Safety News

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Hastings Technology Metals has secured a strategic non-binding MOU with Saudi Arabia’s Ministry of Investment to explore a rare earths processing facility, while reporting encouraging developments at its Yangibana Project and maintaining solid financial footing.

Jameson Resources Limited has made significant progress in environmental approvals for its Crown Mountain Hard Coking Coal Project, while community and political backing for the coal sector in Canada strengthens. The company plans to resubmit its Environmental Impact Statement by mid-2025.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Galena Mining Limited reports a challenging December quarter at its 60%-owned Abra Base Metals Mine, marked by production declines and ongoing voluntary administration. The company appoints a new CEO for Abra and explores recapitalisation options to stabilise operations.

Carbine Resources reports steady progress on its Muchea West silica sand mining licence application, engaging environmental consultants to support upcoming approvals. The company also continues exploration efforts at its Down South project.

HITIQ Limited has extended its Premier League partnership by 18 months with a 60% contract value increase, appointed a new Chief Marketing Officer, and raised an additional $3 million to accelerate global growth.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Image Resources NL has made significant strides in advancing its Atlas Project, overcoming bushfire disruptions and securing a US$20 million prepayment facility to fully fund operations through to first revenue, with commissioning and initial production on track for early 2025.

Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.

Carawine Resources has updated the market with its December 2024 quarterly report, highlighting exploration progress in the Paterson province and an impending court hearing over a compulsory acquisition by major shareholder QGold.